[go: up one dir, main page]

WO2010124009A3 - Fully human anti-vegf antibodies and methods of using - Google Patents

Fully human anti-vegf antibodies and methods of using Download PDF

Info

Publication number
WO2010124009A3
WO2010124009A3 PCT/US2010/031921 US2010031921W WO2010124009A3 WO 2010124009 A3 WO2010124009 A3 WO 2010124009A3 US 2010031921 W US2010031921 W US 2010031921W WO 2010124009 A3 WO2010124009 A3 WO 2010124009A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
fully human
methods
human anti
vegf antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/031921
Other languages
French (fr)
Other versions
WO2010124009A2 (en
Inventor
Sumant Ramachandra
Chin-Yi Huang
Linda Masat
Chao Bai Huang
Walter Robert Bishop
Toshihiko Takeuchi
Seema Kantak
Jo Ann Horowitz
Mohamed H. Ladha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd
Merck Sharp and Dohme LLC
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd
Schering Corp
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd, Schering Corp, Xoma Technology Ltd USA filed Critical Xoma Technology Ltd
Publication of WO2010124009A2 publication Critical patent/WO2010124009A2/en
Publication of WO2010124009A3 publication Critical patent/WO2010124009A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen- binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
PCT/US2010/031921 2009-04-21 2010-04-21 Fully human anti-vegf antibodies and methods of using Ceased WO2010124009A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17138009P 2009-04-21 2009-04-21
US61/171,380 2009-04-21

Publications (2)

Publication Number Publication Date
WO2010124009A2 WO2010124009A2 (en) 2010-10-28
WO2010124009A3 true WO2010124009A3 (en) 2011-01-06

Family

ID=43011738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/031921 Ceased WO2010124009A2 (en) 2009-04-21 2010-04-21 Fully human anti-vegf antibodies and methods of using

Country Status (1)

Country Link
WO (1) WO2010124009A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789138A (en) * 2016-10-04 2019-05-21 株式会社钟根堂 For treating the histone deacetylase inhibitor of hematologic cancers and the pharmaceutical composition of proteasome inhibitor or immunoregulation medicament

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009317A (en) 2005-02-03 2008-01-30 Gen Hospital Corp Method for treating gefitinib resistant cancer.
CN103110948A (en) 2005-11-04 2013-05-22 惠氏公司 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or HKI-272
KR101477824B1 (en) 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. Compositions and methods for the diagnosis and treatment of cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2958968T3 (en) 2008-06-17 2024-02-16 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HUE061640T2 (en) 2009-04-06 2023-07-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SI2707030T1 (en) 2011-05-09 2020-10-30 Mayo Foundation For Medical Education And Research Cancer treatments
LT2758073T (en) 2011-09-23 2019-01-10 Oncomed Pharmaceuticals, Inc. Vegf/dll4 binding agents and uses thereof
CN103664797A (en) * 2012-09-25 2014-03-26 杨子娇 Compounds for treating narrow chamber angle and application thereof
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
US9388239B2 (en) * 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
CN113134095A (en) 2014-06-16 2021-07-20 梅约医学教育与研究基金会 Treatment of myeloma
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
PE20170242A1 (en) * 2014-10-06 2017-03-30 Mayo Foundation CARRIER-ANTIBODY COMPOSITIONS AND METHODS TO MAKE THEM AND USE THEM
CA2966042A1 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3783022A3 (en) * 2016-08-23 2021-06-30 MedImmune Limited Anti-vegf-a antibodies and uses thereof
ES2937291T3 (en) 2016-09-01 2023-03-27 Mayo Found Medical Education & Res Compositions of Agents That Bind to the PD-L1 Transporter and Methods of Using Them to Treat Cancers
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2019110071A (en) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч METHODS FOR TREATMENT OF MALIGNANT NOMINATIONS EXPRESSING PD-L1
CN109890422A (en) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 Taxol-albumin-binding agent composition and the method for using and preparing the composition
CN106929513A (en) * 2017-04-07 2017-07-07 东南大学 The nano antibody of mRNA codings and its application
CN108379566B (en) * 2018-02-01 2020-06-16 郑州大学 Tumor-like human umbilical vein endothelial cell vaccine and application thereof in cancer resistance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133706A2 (en) * 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133706A2 (en) * 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789138A (en) * 2016-10-04 2019-05-21 株式会社钟根堂 For treating the histone deacetylase inhibitor of hematologic cancers and the pharmaceutical composition of proteasome inhibitor or immunoregulation medicament

Also Published As

Publication number Publication date
WO2010124009A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2010124009A3 (en) Fully human anti-vegf antibodies and methods of using
WO2009055343A3 (en) Fully human anti-vegf antibodies and methods of using
MX2009004027A (en) Fully human anti-vegf antibodies and methods of using.
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
PH12017500864A1 (en) Anti-notch1 antibodies
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
IN2012DN00863A (en)
WO2012024650A3 (en) Anti-ngf antibodies and their use
MY165273A (en) Anti-cd48 antibodies and uses thereof
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2011011670A (en) Dual variable domain immunoglobulins and uses thereof.
SG195072A1 (en) Cd3-binding molecules capable of binding to human and non-human cd3
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012004415A (en) Dual variable domain immunoglobulins and uses thereof.
MX2012001262A (en) Dual variable domain immunoglobulins and uses thereof.
MX2011011669A (en) Dual variable domain immunoglobulins and uses thereof.
TW200736275A (en) Methods and compositions for treating allergic diseases
AU2014227664A8 (en) Dual specific binding proteins directed against TNFalpha
PL2917229T3 (en) Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof
WO2011083091A8 (en) Methods for treating pancreatic cancer
WO2011130603A3 (en) Anti-vla-4 antibodies
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10767714

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10767714

Country of ref document: EP

Kind code of ref document: A2